Quick, Easy Access to the Information You Need
To help patients with access to Portola medications, stay informed about CMS policies, industry news and perspectives.
What is NTAP and how can it help patients?
New therapies and technologies may not always be factored into hospital budgets. In an effort to encourage patient access to these innovations, the Centers for Medicare and Medicaid Services (CMS) launched the New Technology Add-on Payment (NTAP) program for Part A Medicare.
In addition to the MS-DRG payment, treatments with NTAP designation may qualify institutions for an additional payment typically equal to the lesser of (i) 65% of the estimated cost of the new technology or medical service or (ii) 65% of the difference between the full DRG payment and the hospital’s estimated cost for the case.
As your institution considers NTAP reimbursement, it helps to understand how manufacturers gain NTAP designation:
- Drug, medical service or technology must be NEW.
- Drug, medical service or technology must incur considerable COST, such that the DRG rate otherwise applicable may be determined to be inadequate.
- Drug, medical service or technology must demonstrate a substantial CLINICAL IMPROVEMENT over existing services or technologies.
This means your institution may be eligible to receive additional reimbursement on these approved drugs, services and devices. The resources below will help you navigate through the NTAP submission process.
New Technology Add-on Payment (NTAP) Brochure
Understand NTAP reimbursement for novel life-saving agents, including eligibility criteria and trends.Download
New Technology Add-on Payment (NTAP) Flashcard
Educate your practice on resource and utilization costs for Factor Xa (FXa) inhibitor-related bleeds and how NTAP may support access.Download
Learn about the services offered under the Portola Access Navigator program and how you can enroll for support.Download